CTT Pharmaceutical buys 2,100 shares at $0.055

CTT PHARMACEUTICAL HOLDINGS, INC.

Rhea-AI Filing Summary

CTT PHARMACEUTICAL HOLDINGS, INC. (CTTH), as reporting person, disclosed a purchase of its CTTH common stock. On 2026-08-24, it purchased 2,100 shares at a price of $0.055 per share in an open market or private transaction, bringing the reported directly held position to 9,360,756 shares after the transaction.

Insider Trade Summary

Net Buyer: 2,100 shares

Net Buy 1 txn

Insider CTT PHARMACEUTICAL HOLDINGS, INC.

Role CEO

Bought 2,100 shs ($115.50)

Type	Security	Shares	Price	Value
Purchase	CTTH	2,100	$0.055	$115.50

Holdings After Transaction: CTTH — 9,360,756 shares (Direct)

Key Figures

Shares purchased: 2,100 shares Purchase price per share: $0.055 per share Shares owned after transaction: 9,360,756 shares +1 more

4 metrics

Shares purchased 2,100 shares Non-derivative purchase on 2026-08-24

Purchase price per share $0.055 per share Price for 2,100 CTTH shares purchased on 2026-08-24

Shares owned after transaction 9,360,756 shares Direct ownership reported following the 2026-08-24 purchase

Net buy shares 2,100 shares Net of buys and sells across all reported transactions

Key Terms

non-derivative, open market or private transaction, direct ownership

3 terms

non-derivative financial

"The transaction is classified as a non-derivative acquisition of common stock"

open market or private transaction financial

"Transaction code P described as a Purchase in open market or private transaction"

direct ownership financial

"Ownership type for the reported shares is classified as direct ownership"

FAQ

What insider transaction did CTTH report on this Form 4?

The reporting person for CTT PHARMACEUTICAL HOLDINGS, INC. (CTTH) reported purchasing 2,100 shares of CTTH common stock on 2026-08-24 in a non-derivative transaction.

At what price were the CTTH shares purchased in this Form 4 filing?

The reported purchase price for CTTH shares was $0.055 per share for the 2,100 shares acquired on 2026-08-24.

How many CTTH shares are held after the reported Form 4 transaction?

After the reported transaction, the filing shows total directly held CTTH shares of 9,360,756.

Does this CTTH Form 4 show a purchase or a sale of shares?

This Form 4 for CTTH reports a purchase of shares, coded as a P transaction and classified as a non-derivative acquisition of 2,100 shares.

Were any derivative securities involved in the CTTH Form 4 transaction?

No. The filing reports only a non-derivative transaction in CTTH common stock and shows no derivative transactions in the derivative summary.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/24/2026 - 09:03 PM Accepted by SEC EDGAR 08/24/2026 - 09:02 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CTT PHARMACEUTICAL HOLDINGS, INC.

(Last) (First) (Middle)

1646 W. SNOW AVE SUITE 138

(Street)

TAMPA FLORIDA 33606

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CTT PHARMACEUTICAL HOLDINGS, INC. [ CTTH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
CTTH	08/24/2026		P		2,100	A	$0.055	9,360,756	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	Ryan Khouri	08/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)